

1 **«RT-LAMP-CRISPR-Cas13a technology as a promising diagnostic tool for the**
2 **SARS-CoV-2 virus»**

3 Concha Ortiz-Cartagena^{1,2}, Laura Fernández-García^{1,2}, Lucia Blasco^{1,2}, Olga Pacios^{1,2}, Inés
4 Bleriot^{1,2}, María López^{1,2,3}, Rafael Cantón^{2,3,4} and María Tomás^{1,2,3*}

- 5
- 6 1. Microbiology Translational and Multidisciplinary (MicroTM)-Research Institute Biomedical
7 A Coruña (INIBIC); Microbiology Department, Hospital A Coruña (CHUAC); University of A
8 Coruña (UDC), A Coruña, Spain;
 - 9 2. Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) the
10 behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC);
 - 11 3. Spanish Network for Research in Infectious Diseases (REIPI) and CIBER de Enfermedades
12 Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain;
 - 13 4. Microbiology Department, Hospital Ramón y Cajal-IRYCIS, Madrid.
- 14
15
16
17
18
19
20
21
22

23 *Correspondence: Maria Tomás
24 Email: MA.del.Mar.Tomas.Carmona@sergas.es;
25 Tel.: +34 981176399; Fax: +34 981178273.

26
27
28
29
30
31
32 **Running title:** SARS-CoV-2 detection by RT-LAMP-CRISPR-Cas13a technology

33 **Keywords:** COVID-19, SARS-CoV-2, RT-RPA, RT-LAMP, CRISPR-Cas13a

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.29.22277060>; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

34 **Abstract**

35 At the end of 2019, the new coronavirus, SARS-CoV-2, began a pandemic that persists to date
36 and which has caused more than 6.2 million deaths. In the last couple of years, researchers have
37 made great efforts to develop a diagnostic technique that maintains high levels of sensitivity and
38 specificity, since an accurate and early diagnosis is required to minimize the prevalence of SARS-
39 CoV-2 infection. In this context, CRISPR-Cas systems are proposed as promising tools for
40 development in diagnostic techniques due to their high specificity, highlighting that Cas13
41 endonuclease discriminates single nucleotide changes and displays a collateral activity against
42 single stranded RNA molecules. With the aim of improve the sensitivity of the diagnosis, this
43 technology is usually combined with isothermal pre-amplification reactions (SHERLOCK,
44 DETECTR). Basing on this, we have developed an RT-LAMP-CRISPR-Cas13a for SARS-CoV-2 virus
45 detection in nasopharyngeal samples without using RNA extraction kit that exhibited 100 %
46 specificity and 83 % sensitivity, as well as a positive predictive value of 100 % and a negative
47 predictive value of 100%, 81%, 79.1% and 66.7 % in <20 Ct, 20-30 Ct, >30 Ct and total Ct
48 values, respectively.

49

50 **Importance**

51 During Covid19 crisis has driven the development innovative molecular diagnose including the
52 CRISPR-Cas technology. This work we have performed a protocol working with RNA-extraction
53 kit free samples, places RT-LAMP-CRISPR-Cas13a technology at the top of rapid and specific
54 diagnostic methods for COVID19 due to the high levels of specificity (100%), sensitivity (83%),
55 PPV (100%) and NPV (81% in high loads viral) obtained in clinical samples.

56

57

58

59

60

61

62

63

64 Introduction

65 Since their emergence at the beginning of the 21st century, coronaviruses have been recognized
66 as a health concern because of their ability to cause severe respiratory infections in humans. At
67 the end of 2019, a new coronavirus appeared, SARS-CoV-2, producing a novel illness, COVID-19,
68 and showing two remarkable characteristics. On the one hand, the virus causes the development
69 of an unusual viral pneumonia and, on the other hand, it is highly transmissible, and thus spreads
70 rapidly [1-3]. This led to the SARS-CoV-2 pandemic that persists to date and which has caused
71 more than 6.2 million deaths (WHO COVID-19 Dashboard <https://covid19.who.int/>).

72 Fortunately, vaccination campaigns have decreased the incidence of COVID-19 [4]. However,
73 specialists claim that this virus is likely to coexist with us for a long time as the price of vaccines
74 and the stability-necessary cold chain make it difficult for the vaccine to reach the most remote
75 places in the world, as SARS-CoV-2 does. Together with the fact that no efficient therapy has
76 been developed for COVID-19, this indicates that accurate and early diagnosis in point of care
77 (POC) testing is required to minimize the prevalence of SARS-CoV-2 infection [1-3].

78 In the last couple of years, researchers have made great efforts to develop a diagnostic
79 technique that maintains high levels of sensitivity and specificity, without the need for expensive
80 equipment or highly trained personnel for its implementation. Such a diagnostic technique
81 would allow the detection of SARS-CoV-2 infection in health centres, as well as at home or in the
82 field, which would accelerate the identification of infected patients, enabling prompt treatment
83 and halting the spread of SARS-CoV-2 worldwide [5].

84 The use of nucleic-acid as biomarkers has become the diagnostic gold standard, because of the
85 species specificity of the technique and because DNA and RNA can be amplified [6].

86 Although detection of nucleic acids has been linked to the polymerase chain reaction (PCR) and
87 quantitative PCR (qPCR), these amplification methods increase the associated costs and must be
88 carried out by specialized personnel. Consequently, isothermal amplification reactions are
89 becoming more important in the diagnosis of COVID-19 [5]. Although different methods of
90 isothermal amplification are available, recombinase polymerase amplification (RPA) and loop-
91 mediated isothermal amplification (LAMP) reactions are the most commonly used in research.
92 The LAMP-based technique has displayed greater specificity than RPA [5, 7]. LAMP had
93 previously been used to detect several microorganisms, and the aforementioned mentioned
94 advantages led to its optimization for COVID-19 diagnosis, as it has been applied in association
95 with other techniques which increase the diagnostic specificity, such as clustered regularly

96 interspaced short palindromic repeats (CRISPR)-associated protein (CRISPR-Cas) systems [5, 8-
97 10].

98 Naturally, CRISPR-Cas systems provide adaptive immunity for bacteria and archaea, as they
99 collect genomic fragments (spacers) from foreign elements (bacteriophages, plasmids and other
100 mobile genetic elements), which are expressed in an RNA molecule form (crRNA) that guides an
101 endonuclease protein (Cas) to the pathogen, for final degradation of its nucleic-acid material
102 [11, 12].

103 Since their discovery, CRISPR-Cas systems have revolutionized the field of molecular biology.
104 Initially they were presented as highly specific tools for genome editing. However, they are also
105 applicable for the diagnosis and treatment of infectious diseases and are now considered key
106 for development in these areas [11, 12].

107 Class 2 CRISPR-Cas systems have a simpler effector structure, which makes them more attractive
108 for use in genome editing, diagnosis and treatment. In this class, Cas12 and Cas13 proteins
109 display non-specific endonuclease activity when activated (collateral activity) against single
110 stranded DNA (ssDNA) and RNA (ssRNA) respectively. This feature could be applied in clinical
111 diagnosis, taking advantage of the reporter molecule target of this activity (collateral-based
112 detection), which acts by amplifying the detection signal. Therefore, Cas12 and Cas13 are
113 proposed as the most promising tools for use in diagnostic techniques, with the latter being
114 particularly important in terms of specificity as it has the ability to discriminate single nucleotide
115 changes [11].

116 Researchers recently developed two novel assays for detecting SARS-Cov-2 based on CRISPR-
117 Cas technology: DETECTR and SHERLOCK. The DETECTR technique uses reverse transcription-
118 LAMP (RT-LAMP) for amplification and Cas12 as an endonuclease, while SHERLOCK uses RT-RPA
119 for amplification and Cas13 [13, 14]. On the basis of these works, in this study we describe the
120 development and optimization of a LAMP-CRISPR-Cas13a technique for the diagnosis of SARS-
121 CoV-2 infection in clinical samples in a process that does not require RNA-extraction or
122 purification. With this technique, high levels of sensitivity and specificity, comparable to those
123 associated with qPCR, were obtained.

124 **Material and methods**

125 Study of the state of the art

126 A study of the state of the art was conducted with the aim of comparing the use of different
127 novel diagnostic techniques. First, we conducted a search in PubMed with “qPCR diagnosis

128 COVID19” as keywords and compared the output with the number of publications on RT-LAMP
129 and RT-LAMP-CRISPR strategies for COVID-19 diagnosis [15]. Finally, we collected data on the
130 different sensitivity, specificity, positive predictive value (PPV) and negative predictive value
131 (NPV) from 10 papers related to RT-LAMP and 10 papers on the RT-LAMP-CRISPR-Cas COVID19
132 diagnostic technique [16-35]. We used the results to calculate the parameters needed for the
133 comparison.

134 In silico analysis and design of RT-LAMP primers, crRNAs and RNA reporters

135 The nucleocapside gene (ID: ON394272.1) of the SARS-CoV-2 virus was selected for study. The
136 target sequence was analyzed in silico with the aim of designing specific primers for
137 amplification of a genetic region without any previously described mutation (N gene region 12-
138 213 pb named as N2 gene) [36]. Three pairs of LAMP primers were designed using the
139 PrimerExplorer V5 software (F3-B3, FIP-BIP, Floop-Bloop) to amplify the SARS-CoV-2 N2 gene.
140 The FIP LAMP primer contained the T7 polymerase promoter in its sequences for the subsequent
141 transcription step (Table 1).

142 Two different RNA reporters (reporter 1 and 2) were used to reveal the results in order to select
143 the one with the best signal. Both contained a single isomer derivative of fluorescein
144 modification (FAM) at the 5’ extreme and a biotin molecule at the 3’ extreme (Table 1).

145 Clinical samples

146 Clinical samples were supplied by the Microbiology Service of the Teresa Herrera Materno
147 Infantil Hospital (A Coruña, Spain). The samples (n= 133) were obtained from nasopharyngeal
148 swabs for SARS-CoV-2 detection (Table 2).

149 Sample processing

150 For sample processing, a proteinase K-heat inactivation protocol (PK-HID) was applied to
151 samples from swabs stored in viral transport medium (Gibco®) [37]. Thus, 95 µl aliquots of
152 samples were treated for 15 minutes at 55°C with 5 µl of proteinase K (10 mg/ml, stock)
153 prepared at 1 mg/ml in 100 µl of final volume and heat-inactivated at 98°C for 5 minutes. Finally,
154 extracted RNA samples were stored at -80°C.

155 RT-LAMP reaction

156 Amplification by the RT-LAMP (WarmStart® LAMP Kit (DNA & RNA), NEB) reaction was
157 performed following the manufacturer’s protocol. Briefly, RNA samples (5 µl) were added to a
158 reaction mix containing 12.5 µl of WarmStart LAMP 2X Master Mix and 2.5 µl of Primer Mix 10X

159 (FIP/BIP 16 μ M, F3/B3 2 μ M, LOOPF/LOOPB 4 μ M, stock) adjusted to a final volume of 25 μ l with
160 dH₂O. The reactions were incubated at 65°C for 1 hour.

161 Collateral-based detection

162 Each Cas13a-based detection reaction was incubated at 37°C for 30 min with the following
163 reaction components: 2 μ l of cleavage buffer 10X (200 mM HEPES, 90 mM magnesium chloride,
164 600 mM sodium chloride), 0.5 μ l of dNTPs (HiScribe™ T7 Quick High Yield RNA Synthesis Kit), 0.5
165 μ l of T7 polymerase (HiScribe™ T7 Quick High Yield RNA Synthesis Kit), 20 U of RNase murine
166 inhibitor (NEB), 0.15 μ l Cas13a endonuclease (25 nM, MCLAB), 0.5 μ l crRNA (50 nM, IDT), 2 μ l of
167 reporter (1000 nM, IDT) and 5 μ l of cDNA sample, adjusted to a final volume of 20 μ l with dH₂O.

168 Different concentrations of Cas13a and crRNA (200, 100, 50 nM) were tested, and two different
169 enzyme:guide molar ratios were used (1:1 and 2:1).

170 Hybridetect lateral flow

171 Results were revealed by the HybriDetect lateral flow assay as described by the manufacturer
172 (Milenia Biotec), with some modifications. Briefly, 20 μ l of collateral-based detection product
173 was mixed with 80 μ l of assay buffer in a 96-well plate. Immediately, the gold-extreme of the
174 strip was submerged in the mix and held for 2-3 minutes.

175 Following the manufacturer's instructions, reactive strips required calibration before application
176 for management of an optimal RNA reporter concentration and, as mentioned, reporters 1 and
177 2 were tested. Results obtained with two different assay buffers were also compared: the kit
178 assay buffer and the same supplemented with 5% polyethylenglycol (PEG).

179 The results obtained, i.e. true positive (TP), false positive (FP), false negative (FN) and true
180 negative (TN), were used to calculate the following parameters: sensitivity (TP/TP+FN),
181 specificity (TN/TN+FP), positive predictive value (TP/TP+FP) and negative predictive value
182 (TN/TN+FN).

183 Limit of detection

184 For estimating the number of initial SARS-CoV-2 viral particles that the CRISPR-Cas13a
185 technology was able to detect, we serially diluted (1:10) the RNA extracted using hospital
186 equipment from two clinical samples with Ct 20 and Ct 25. Finally, 5 μ L aliquots of each dilution
187 were used for calculation of the limit of detection (LOD). Here, we applied an estimated
188 correlation between Ct value and the viral load.

189

190 Statistical analysis

191 Statistical analysis was conducted using the GraphPad Prism9 program to construct a receiver
192 operating characteristic (ROC) curve with a confidence interval of 95% (Wilson/Brown method)
193 and to construct a scatter plot of two groups (false negative and true positive samples) against
194 the Ct of each sample.

195 **Results**

196 Analysis of the state of the art

197 We obtained an output of more than 7000 articles as a result of “qPCR diagnosis COVID19”
198 search, of almost 4000 in 2021 alone. This result was compared with findings of Bhatt A. et al.
199 [15] concerning papers related to RT-LAMP and CRISPR for SARS-CoV-2 diagnosis. Of these, we
200 analyzed 10 articles on the RT-LAMP technique and 10 articles related to RT-LAMP-CRISPR-Cas
201 technology, finding that only 1 applied the endonuclease Cas13 for SARS-CoV-2 diagnosis always
202 on samples treated with an RNA extraction kit [35] (Table 3).

203 Data collected from RT-LAMP articles were used to determine the ranges of values of the
204 parameters considered: sensitivity, 81 % - 98 %; specificity, 36 % -100 %; PPV, 86 % - 100 %; and
205 NPV, 78 % - 99 % (Table 3A). The results showed that major efforts have been made to detect
206 SARS-CoV-2 virus in RNA purified samples (8/10), although RNA extraction-free research has also
207 yielded potentially useful results (sensitivity >94 %, specificity and PPV 100 %, NPV >92 %).
208 However, the highest levels of sensitivity and specificity were obtained in the projects involving
209 extracted viral RNA (Table 3A).

210 Most reviewed papers (8/10) related to RT-LAMP-CRISPR-Cas technology used samples treated
211 with extraction kits. Moreover, only 1 study applied the Cas13 enzyme as an effector protein
212 and used RNA extracted by kit. In this case, the values for calculated data were 73 %-97 % for
213 sensitivity, 95 %-100 % for specificity, 90 %-100 % for PPV and 50 %-95 % for NPV (Table 3B).

214 SARS-CoV-2 detection

215 The best results for collateral-based detection reaction were achieved with 50 nM Cas13a
216 enzyme and a molar ratio for Cas13a:crRNA of 2:1. On the other hand, HybriDetection lateral
217 flow showed the higher sensitivity when reporter 2 was used at a final concentration of 1000
218 nM and the assay buffer was supplemented with 5 % PEG.

219 The LOD determination of the CRISPR-Cas13a based technology revealed that this technique
220 detects as few as 1-10 SARS-CoV-2 particles (Figure 2). After PK-HID treatment, the LAMP-
221 CRISPR-Cas13a technique was able to correctly detect samples with Ct<20 as positive. From

222 samples with Ct 20-30 and Ct>30, the technique identified coronavirus as present in 83.3 % and
223 62.5 % of the samples, respectively (Figure 3C). Finally, the CRISPR-Cas13a technology did not
224 detect SARS-CoV-2 infection in negative samples (Figure 3A). Based on the results obtained
225 (Figure 3B), we estimated that the LAMP-CRISPR-Cas13a method for COVID-19 detection
226 exhibits 100 % specificity and 83 % sensitivity, as well as a positive predictive value (PPV) of 100
227 % and a negative predictive value (NPV) of 100%, 81%, 79.1% and 66.7 % in <20 Ct, 20-30 Ct,
228 >30 Ct and total Ct values, respectively (Figure 3C). The statistical analysis yielded a ROC curve
229 with an area under the curve (AUC) of 0.84 with a 95 % CI of 0.73-0.93 (Figure 4A); in addition,
230 examination of the scatter plot revealed that diagnostic results could be confused in
231 nasopharyngeal samples with Ct>30 (Figure 4B).

232 **Discussion**

233 Study of the state of the art revealed that greater efforts must be made to innovate in diagnostic
234 methods, as Bhatt A. et al. [15] found 1286 papers related to RT-LAMP and CRISPR for SARS-
235 CoV-2 diagnosis, in contrast to the 7000 studies involving qPCR (surprisingly only 98 of these
236 applied RT-LAMP integrated with CRISPR-Cas technology). This indicates that efforts should also
237 be focused on developing more efficient RT-LAMP-CRISPR-Cas protocols without purification of
238 RNA, which would reduce the cost of the testing and also produce results faster. Only 3 out of
239 the 20 papers reviewed did not use an RNA extraction kit [16, 17, 27]. In addition, there are
240 several advantages to the application of Cas13 endonuclease, as it has been reported to be more
241 specific than other effector proteins [11].

242 In this work, our research group has developed an RT-LAMP-CRISPR-Cas13a protocol for
243 diagnosing SARS-CoV-2 infection with an LOD of 10 viral copies, which is similar to the LOD of
244 the qPCR method, considered the gold standard for diagnosis of COVID-19 [38]. Furthermore, it
245 has been reported that the qPCR for SARS-CoV-2 detection has a limited sensitivity of 60-71 %
246 [39], while the RT-LAMP-CRISPR-Cas13a technology increased this value significantly, up to 83
247 %.

248 Considering the criteria recommended by the WHO, the novel technique fulfils the three key
249 features of accuracy, accessibility and affordability. This is because, on the one hand, it showed
250 an accuracy $((TP+TN)/total)$ of 87.2 %, and, on the other hand, it is both accessible and affordable
251 as neither specific equipment nor trained personnel are required, and the amount of enzymes
252 needed per reaction is quite low.

253 Comparing our results on sensitivity, specificity, PPV and NPV with those obtained in previous
254 studies, we found that the specificity and PPV values of the RT-LAMP-CRISPR-Cas13a technology

255 were higher than those from 7 out of 10 RT-LAMP papers reviewed [19-25] and in one case the
256 sensitivity of the novel technique was even higher [18]. Moreover, this technique showed higher
257 sensitivity and NPV values than those from 2 out of 10 RT-LAMP-CRISPR papers reviewed which
258 applied RNA extraction kit on the clinical samples [33, 35]. Among the others, 7 out of 8 studies
259 used DNA target-endonuclease effectors, and thus higher sensitivity could be obtained due to
260 the intrinsic stability of DNA in contrast to RNA molecules. The lower sensitivity of the RT-LAMP-
261 CRISPR-Cas13a protocol (83 %) than described in a previous study (97.4 %) could be explained
262 by the fact that the researchers used an RNA extraction kit (Direct-zol kit), so that the RNA was
263 purified and concentrated, and also the results were revealed by fluorescence [26].

264 ROC analysis has become a popular method for evaluating the accuracy of medical diagnostic
265 systems, as it provides accurate indices for the techniques tested that are not distorted by
266 fluctuations caused by the use of arbitrarily chosen decision criteria or cut-off points [40]. The
267 AUC determines the inherent ability of the test to correctly identify a person as infected or not,
268 where an AUC value of 0.5 indicates an absence of capacity of discrimination between infected
269 and healthy populations, a value of 0.5-0.7 is related to unsatisfactory discrimination; ability is
270 acceptable when value is between 0.7-0.8, it is excellent for values contained in the ratio 0.8-
271 0.9 and perfect when the AUC is close to 1 [41]. The value of the AUC ROC curve calculated by
272 statistical analysis validated our RT-LAMP-CRISPR-Cas13a technique as a reliable diagnostic
273 method. Furthermore, results shown in the scatter plot figure indicate that this protocol
274 provides less accurate diagnostics when viral loads are low. However, we should bear in mind
275 that at this stage of infection, individuals present almost no risk of being contagious [42, 43].

276 In summary, the high levels of specificity, sensitivity, PPV and NPV obtained with this
277 promising protocol working with RNA-extraction kit free samples, places LAMP-CRISPR-Cas13a
278 technology at the top of rapid and specific diagnostic methods for infectious diseases. Thus, this
279 technique could be established as a diagnostic tool for detecting other infectious diseases, such
280 as those caused by multiresistant pathogens. However, Cas13 detection methods should be
281 optimized to enable direct diagnosis without prior amplification of nucleic acids.

282 **Acknowledgment:** This study was funded by grant PI19/00878 awarded to M. Tomás, within the
283 State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological
284 Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General
285 Directorate for Evaluation and Promotion of Research - European Regional Development Fund
286 "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the
287 Research in Infectious Diseases (REIPI, RD16/0016/0006 and RD16/CIII/0004/0002), Instituto de

288 Salud Carlos III FEDER Experiments were funded by grant IN607A 2020/38 within the GAIN
289 (Agencia Gallega de Innovación) COVID plan and by the Study Group on Mechanisms of Action
290 and Resistance to Antimicrobials, GEMARA (SEIMC, <http://www.seimc.org/>) and finally, ESCMID
291 grant (European Society of Clinical Microbiology and Infectious Diseases) awarded to L.
292 Fernández-García. O. Pacios, L. Fernández-García and M. López were financially supported by
293 the grants IN606A-2020/035, IN606B-2021/013 and IN606B-2018/008, respectively (GAIN,
294 Xunta de Galicia). I. Bleriot was financially supported by pFIS pro- 511gram (ISCI, FI20/00302).
295 Ethical approval was granted by the Galicia Drug Research Ethics Committee (CEIm-G) and the
296 internal ethical from Institute of Research A Coruña (INIBIC) from Coruña hospital (HUAC)
297 (2020/207).

298 **Conflicts of interest:** The authors declare that there are no conflicts of interest.
299
300
301
302
303
304
305
306
307

308

309

310

311

312

313

314

315

316

317

318

319

320 **References**

- 321 1. Stasi, C., et al., *Treatment for COVID-19: An overview*. Eur J Pharmacol, 2020. **889**: p.
322 173644.
- 323 2. Salian, V.S., et al., *COVID-19 Transmission, Current Treatment, and Future Therapeutic*
324 *Strategies*. Molecular Pharmaceutics, 2021. **18**(3): p. 754-771.
- 325 3. Taleghani, N. and F. Taghipour, *Diagnosis of COVID-19 for controlling the pandemic: A*
326 *review of the state-of-the-art*. Biosens Bioelectron, 2021. **174**: p. 112830.
- 327 4. Vitiello, A., et al., *COVID-19 vaccines and decreased transmission of SARS-CoV-2*.
328 *Inflammopharmacology*, 2021. **29**(5): p. 1357-1360.
- 329 5. Rai, P., et al., *Detection technologies and recent developments in the diagnosis of COVID-*
330 *19 infection*. Appl Microbiol Biotechnol, 2021. **105**(2): p. 441-455.
- 331 6. Kaminski, M.M., et al., *CRISPR-based diagnostics*. Nat Biomed Eng, 2021. **5**(7): p. 643-
332 656.
- 333 7. Zou, Y., M.G. Mason, and J.R. Botella, *Evaluation and improvement of isothermal*
334 *amplification methods for point-of-need plant disease diagnostics*. PLoS One, 2020.
335 **15**(6): p. e0235216.
- 336 8. Silva, S., K. Pardee, and L. Pena, *Loop-Mediated Isothermal Amplification (LAMP) for the*
337 *Diagnosis of Zika Virus: A Review*. Viruses, 2019. **12**(1).
- 338 9. Seki, M., et al., *Loop-Mediated Isothermal Amplification Methods for Diagnosis of*
339 *Bacterial Meningitis*. Front Pediatr, 2018. **6**: p. 57.
- 340 10. Kashir, J. and A. Yaqinuddin, *Loop mediated isothermal amplification (LAMP) assays as*
341 *a rapid diagnostic for COVID-19*. Med Hypotheses, 2020. **141**: p. 109786.
- 342 11. Strich, J.R. and D.S. Chertow, *CRISPR-Cas Biology and Its Application to Infectious*
343 *Diseases*. J Clin Microbiol, 2019. **57**(4).
- 344 12. Ding, W., Y. Zhang, and S. Shi, *Development and Application of CRISPR/Cas in Microbial*
345 *Biotechnology*. Front Bioeng Biotechnol, 2020. **8**: p. 711.
- 346 13. Chen, J.S., et al., *CRISPR-Cas12a target binding unleashes indiscriminate single-stranded*
347 *DNase activity*. Science, 2018. **360**(6387): p. 436-439.
- 348 14. Kellner, M.J., et al., *SHERLOCK: nucleic acid detection with CRISPR nucleases*. Nat Protoc,
349 2019. **14**(10): p. 2986-3012.
- 350 15. Bhatt, A., et al., *Diagnostic efficiency of RT-LAMP integrated CRISPR-Cas technique for*
351 *COVID-19: A systematic review and meta-analysis*. Pathog Glob Health, 2022: p. 1-11.
- 352 16. DeFina, S.M., et al., *SalivISION: a rapid saliva-based COVID-19 screening and diagnostic*
353 *test with high sensitivity and specificity*. Sci Rep, 2022. **12**(1): p. 5729.

- 354 17. Lai, M.Y., et al., *RNA purification-free detection of SARS-CoV-2 using reverse*
355 *transcription loop-mediated isothermal amplification (RT-LAMP)*. Trop Med Health,
356 2022. **50**(1): p. 2.
- 357 18. Promlek, T., et al., *Performance of colorimetric reverse transcription loop-mediated*
358 *isothermal amplification as a diagnostic tool for SARS-CoV-2 infection during the fourth*
359 *wave of COVID-19 in Thailand*. Int J Infect Dis, 2022. **116**: p. 133-137.
- 360 19. Dong, Y., et al., *Multiplex, Real-Time, Point-of-care RT-LAMP for SARS-CoV-2 Detection*
361 *Using the HFman Probe*. ACS Sens, 2022. **7**(3): p. 730-739.
- 362 20. Schneider, F.S., et al., *Performances of rapid and connected salivary RT-LAMP diagnostic*
363 *test for SARS-CoV-2 infection in ambulatory screening*. Sci Rep, 2022. **12**(1): p. 2843.
- 364 21. Minami, K., et al., *Evaluation of SARS-CoV-2 RNA quantification by RT-LAMP compared*
365 *to RT-qPCR*. J Infect Chemother, 2021. **27**(7): p. 1068-1071.
- 366 22. Tang, Z., et al., *Rapid detection of novel coronavirus SARS-CoV-2 by RT-LAMP coupled*
367 *solid-state nanopores*. Biosens Bioelectron, 2022. **197**: p. 113759.
- 368 23. Kidd, S.P., et al., *Reverse-Transcription Loop-Mediated Isothermal Amplification Has*
369 *High Accuracy for Detecting Severe Acute Respiratory Syndrome Coronavirus 2 in Saliva*
370 *and Nasopharyngeal/Oropharyngeal Swabs from Asymptomatic and Symptomatic*
371 *Individuals*. J Mol Diagn, 2022. **24**(4): p. 320-336.
- 372 24. Agarwal, S., et al., *Lateral flow-based nucleic acid detection of SARS-CoV-2 using*
373 *enzymatic incorporation of biotin-labeled dUTP for POCT use*. Anal Bioanal Chem, 2022.
374 **414**(10): p. 3177-3186.
- 375 25. Kitajima, H., et al., *Clinical COVID-19 diagnostic methods: Comparison of reverse*
376 *transcription loop-mediated isothermal amplification (RT-LAMP) and quantitative RT-*
377 *PCR (qRT-PCR)*. J Clin Virol, 2021. **139**: p. 104813.
- 378 26. Mahas, A., et al., *A Novel Miniature CRISPR-Cas13 System for SARS-CoV-2 Diagnostics*.
379 ACS Synth Biol, 2021. **10**(10): p. 2541-2551.
- 380 27. Bhatt, A., et al., *CLEVER assay: A visual and rapid RNA extraction-free detection of SARS-*
381 *CoV-2 based on CRISPR-Cas integrated RT-LAMP technology*. J Appl Microbiol, 2022.
- 382 28. Pang, B., et al., *Isothermal Amplification and Ambient Visualization in a Single Tube for*
383 *the Detection of SARS-CoV-2 Using Loop-Mediated Amplification and CRISPR*
384 *Technology*. Anal Chem, 2020. **92**(24): p. 16204-16212.
- 385 29. Nguyen, L.T., et al., *A thermostable Cas12b from Brevibacillus leverages one-pot*
386 *discrimination of SARS-CoV-2 variants of concern*. EBioMedicine, 2022. **77**: p. 103926.
- 387 30. Ali, Z., et al., *iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive*
388 *detection of SARS-CoV-2*. Virus Res, 2020. **288**: p. 198129.

- 389 31. Joung, J., et al., *Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing*. N Engl J Med,
390 2020. **383**(15): p. 1492-1494.
- 391 32. Cao, Y., et al., *CRISPR/Cas12a-mediated gold nanoparticle aggregation for colorimetric*
392 *detection of SARS-CoV-2*. Chem Commun (Camb), 2021. **57**(56): p. 6871-6874.
- 393 33. Steens, J.A., et al., *SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting*
394 *and stringent CARF ribonuclease activation*. Nat Commun, 2021. **12**(1): p. 5033.
- 395 34. Yoshimi, K., et al., *CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus*.
396 iScience, 2022. **25**(2): p. 103830.
- 397 35. Santiago-Frangos, A., et al., *Intrinsic signal amplification by type III CRISPR-Cas systems*
398 *provides a sequence-specific SARS-CoV-2 diagnostic*. Cell Rep Med, 2021. **2**(6): p.
399 100319.
- 400 36. Ziegler, K., et al., *SARS-CoV-2 samples may escape detection because of a single point*
401 *mutation in the N gene*. Euro Surveill, 2020. **25**(39).
- 402 37. Genoud, V., et al., *Extraction-free protocol combining proteinase K and heat inactivation*
403 *for detection of SARS-CoV-2 by RT-qPCR*. PLoS One, 2021. **16**(2): p. e0247792.
- 404 38. Chu, D.K.W., et al., *Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an*
405 *Outbreak of Pneumonia*. Clin Chem, 2020. **66**(4): p. 549-555.
- 406 39. Alsharif, W. and A. Qurashi, *Effectiveness of COVID-19 diagnosis and management tools:*
407 *A review*. Radiography (Lond), 2021. **27**(2): p. 682-687.
- 408 40. Hajian-Tilaki, K., *Receiver Operating Characteristic (ROC) Curve Analysis for Medical*
409 *Diagnostic Test Evaluation*. Caspian J Intern Med, 2013. **4**(2): p. 627-35.
- 410 41. Foinquinos, J., et al., *Temporal Validation of a Predictive Score for Death in Children with*
411 *Visceral Leishmaniasis*. J Trop Med, 2021. **2021**: p. 6688444.
- 412 42. Mendoza, E.J., et al., *Two Detailed Plaque Assay Protocols for the Quantification of*
413 *Infectious SARS-CoV-2*. Curr Protoc Microbiol, 2020. **57**(1): p. ecpmc105.
- 414 43. Case, J.B., et al., *Growth, detection, quantification, and inactivation of SARS-CoV-2*.
415 *Virology*, 2020. **548**: p. 39-48.

416

417

418

419

420

421 **Legends of figures and tables:**

422 **Table 1.** Sequences of primers, crRNAs and reporters. Underlined letters indicate overhang T7
423 promotor sequence and lower-case letters indicate scaffold sequence. All primers were supplied
424 by IDT and reporters were supplied by GenScript.

425 **Table 2.** Positive and negative samples for SARS-CoV-2.

426 **Table 3.** A. Table with percentages of sensitivity, specificity, PPV and NPV parameters collected
427 from 10 articles which applies RT-LAMP technology to detect SARS-CoV-2 infection; B. Table with
428 percentages of sensitivity, specificity, PPV and NPV parameters collected form ten articles which
429 applies RT-LAMP-CRISPR technology to detect SARS-CoV-2 infection. Nasopharyngeal swab
430 (**NPS**) and Oropharyngeal Swab (**OPS**).

431 **Figure 1.** Workflow of the novel developed and optimized protocol for infectious diseases
432 diagnosis based on CRISPR-Cas13a technology.

433 **Figure 2.** LOD assay for SARS-CoV-2 detection with N2 gene as target using serial dilutions (1:10)
434 from two samples with different Cts (Ct20 and Ct25, respectively).

435 **Figure 3.** A. Strips for SARS-CoV-2 detection using samples with Cts from 13 to 38 and negative
436 samples as negative controls with numerical results for each interval of Cts (Ct<20, Ct 20-30 and
437 Ct>30); B. Results obtained from N2 gene SARS-CoV-2 detection; C. Table containing specificity,
438 sensitivity, PPV and NPV LAMP-CRISPR-Cas13 technique values from figure 4B data processing.

439 **Figure 4.** A. ROC curve for RT-LAMP-CRISPR-Cas13a technology; B. Scatter plot of two groups:
440 false negative detections and true positive detections with RT-LAMP-CRISPR-Cas13a vs Ct of
441 respective samples.

442

443

444

445

446

447

448

449

450

Name	Sequence	Position in gene
LAMP primers		
F3_N2	TGGACCCCAAATCAGCG	12-29
B3_N2	GCCTTGTCTCGAGGGAAT	195-213
FIP_N2	TGCGTTCTCATTCTGGTTACTGCGAAATTAATACGACTCACTATAGGGAATGCACCCCGCATTACG	-
BIP_N2	CGCGATCAAAACAACGTCGGCCCTTGCCATGTTGAGTGAGA	-
Floop_N2	CAGTTGAATCTGAGGGTCCACCAA	50-73
Bloop_N2	CAAGGTTTACCAATAATACTGCGT	127-151
crRNA		
crRNA_N2	gauuuagacuacccccaaaacgaaggggacuaaaacGGUCCACCAAACGUAAUGCGGGGUGCAU	40-59
Reporters		
Reporter 1	FAM-mArArUrGrGrCmAmArArUrGrGrCmA-Biotin	-
Reporter 2	FAM-UUUUUU-Biotin	-

451 **Table 1.**

452

		Number	Origin	Cycle threshold (Ct)
SARS-CoV-2 samples	Positives	27	Nasopharyngeal	<20
		48	Nasopharyngeal	20-30
		24	Nasopharyngeal	>30
	Total	99	-	-
	Negatives	34	Nasopharyngeal	-

453 **Table 2.**

454

455

456

457

458

459

460

461

462

463

464

465

466

467 A.

Sample	RNA extraction kit	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Ref
Saliva	No	94.3	100	100	92.6	[16]
NPS/OPS	No	95.2	100	100	92.6	[17]
NPS	Yes	81.8	100	100	95.2	[18]
NPS	Yes	94.5	99	98.8	95.2	[19]
NPS/Saliva	Yes	85.9	99.5	96.8	97.4	[20]
NPS	Yes	98.1	36.4	93.7	66.7	[21]
NPS	Yes	98	90.9	87.5	98.6	[22]
NPS/OPS/Saliva	Yes	97.8	99.9	99.8	99.9	[23]
NPS	Yes	94.1	60.5	86.7	78.8	[24]
NPS/Saliva	Yes	87	98.5	97.9	90.2	[25]

468

469 B.

Sample	RNA extraction kit	Cas	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Ref
NPS/OPS	Yes	Cas13	97.4	100	100	66.7	[26]
NPS/OPS	No	Cas12	89.7	100	100	78.6	[27]
Respiratory	Yes	Cas12	94	100	100	94.3	[28]
Saliva	Yes	Cas12	87.7	100	100	73.6	[29]
NPS/OPS	Yes	Cas12	85.7	100	100	50	[30]
NPS	Yes	Cas12	93.1	98.5	98.4	93.4	[31]
Respiratory	Yes	Cas12	92.6	100	100	93.1	[32]
NPS	Yes	Csm complex	73.9	100	100	45.5	[35]
NPS	Yes	Cmr complex	77.5	100	100	52.6	[33]
NPS	Yes	Cas3	90	95.2	90	95.2	[34]

470 Table 3.

471

472

473

474

475

476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494





Figure 1.



495


496

497 **Figure 2.**

498


499

500



519 **Figure 3.**

A



B

